After a significant increase in 2023, Danish regions' expenses for subsidized medicines fell by 4.3% in 2024.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Patents require reliability so they can incentivize investments in new technologies, their primary though little-noticed ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Pharma consultant Sanjay Agrawal seeks patent for a new drug formulation targeting cellular ageing, aiming to improve skin health, energy, and vitality.

Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine’s presentations, please visit the ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

The narrative surrounding Nigeria’s recent drug market raid has been dangerously skewed. What many perceive as heavy-handed overreach ...